GlassScriptPhysician profile
Paula S Youngdahl
NPI 1053311449
$2,986.83
in general payments reported to CMS, 2019-2025
29 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $351 · 2021: $283 · 2022: $486 · 2023: $412 · 2024: $391 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.85 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $677.97 | 2019-2024 | Veozah, Myrbetriq |
| Lupin INC. | $303.10 | 2019 | |
| Abbvie INC. | $224.60 | 2019-2023 | Lo Loestrin Fe |
| Cumberland Pharmaceuticals, INC. | $194.39 | 2019-2024 | Caldolor |
| Organon LLC | $181.97 | 2022-2024 | Nexplanon |
| Mylan Pharmaceuticals INC. | $164.58 | 2019-2022 | |
| Becton, Dickinson and Company | $123.22 | 2025 | Arista |
| Therapeuticsmd, INC. | $107.12 | 2019-2022 | |
| Hologic Sales and Service, LLC | $105.39 | 2019-2024 | Myosure Tissue Removal Device, Fluent Fluid Management System, Novasure |
| Amgen INC. | $102.70 | 2019-2024 | Evenity, Prolia |
| Intuitive Surgical, INC. | $84.83 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $77.32 | 2022-2024 | |
| Myovant Sciences INC. | $73.38 | 2021-2022 | |
| Exeltis, USA INC. | $72.20 | 2019-2023 | Slynd |
| Coopersurgical, INC. | $65.97 | 2022-2024 | Paragard T 380a |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $61.35 | 2022 | |
| Sumitomo Pharma America, INC. | $61.34 | 2023-2024 | Myfembree, Gemtesa |
| Avion Pharmaceuticals | $57.00 | 2019-2021 | |
| Pfizer INC. | $47.54 | 2021-2024 | |
| Duchesnay USA Incorporated | $38.93 | 2019 | |
| Mission Pharmacal Company | $29.06 | 2019-2020 | |
| Agile Therapeutics, INC. | $28.89 | 2021-2022 | |
| Urovant Sciences INC | $20.71 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.92 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.71 | 2023 | |
| Radius Health, INC. | $14.26 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.87 | 2019 | |
| Allergan, INC. | $13.60 | 2019 | |
| Boston Scientific Corporation | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Youngdahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.